{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:19:38Z","timestamp":1771341578626,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.semcancer.2019.10.019","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T11:48:18Z","timestamp":1572868098000},"page":"84-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer"],"prefix":"10.1016","volume":"68","author":[{"given":"Ramanathan","family":"Karuppasamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Veerappapillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayoni","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong-Hee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2019.10.019_bib0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ccm.2011.08.003","article-title":"Molecular biology of lung cancer: clinical implications","volume":"32","author":"Larsen","year":"2011","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0010","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5","author":"Cooper","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Cur Opin Genet Dev"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.sjbs.2014.10.002","article-title":"BRAF gene: from human cancers to developmental syndromes","volume":"22","author":"Hussain","year":"2015","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","article-title":"Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies","volume":"8","author":"Hussain","year":"2016","journal-title":"Genome Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1101\/gad.279737.116","article-title":"Carcinoma-associated fibroblasts: orchestrating the composition of malignancy","volume":"30","author":"Gascard","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbcan.2015.08.002","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim Biophys Acta (BBA)-Reviews on Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0050","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/cam4.819","article-title":"Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer","volume":"5","author":"Qin","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0060","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.bbmt.2012.09.020","article-title":"Cancer vaccines and T cell therapy","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0065","first-page":"234","article-title":"Autologous cell therapy: current treatments and future prospects","volume":"21","author":"Kazmi","year":"2009","journal-title":"Wounds"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0070","first-page":"53","article-title":"Immunotherapy in lung cancer","volume":"3","author":"Massarelli","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0075","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/749310","article-title":"Dietary agents in cancer chemoprevention and treatment","volume":"2012","author":"Raffoul","year":"2012","journal-title":"J. Oncol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1475-2891-3-19","article-title":"Nutrition and cancer: a review of the evidence for an anti-cancer diet","volume":"3","author":"Donaldson","year":"2004","journal-title":"Nutr. J."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2015.01.038","article-title":"Dietary agents for prevention and treatment of lung cancer","volume":"359","author":"Khan","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0095","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/cancers7020816","article-title":"Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK","volume":"7","author":"Rothschild","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijc.IJC_505_17","article-title":"Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"54","author":"Pathak","year":"2017","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ijms20010146","article-title":"First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?","volume":"20","author":"Takeda","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/DDDT.S147499","article-title":"Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy","volume":"13","author":"Ali","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41419-019-1561-x","article-title":"S-nitrosylation of the Peroxiredoxin-2 promotes S-nitrosoglutathione-mediated lung cancer cells apoptosis via AMPK-SIRT1 pathway","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0130","first-page":"1","article-title":"Programming of macrophages by UV-irradiated apoptotic cancer cells inhibits cancer progression and lung metastasis","author":"Kim","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0135","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1038\/s41598-019-41653-9","article-title":"Antrodia cinnamomea induces anti-tumor activity by inhibiting the STAT3 signaling pathway in lung cancer cells","volume":"9","author":"Huang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0140","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41419-019-1528-y","article-title":"Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130\/STAT3 signaling pathway","volume":"10","author":"Kuang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s12276-019-0209-3","article-title":"Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response","volume":"51","author":"Jiang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41419-019-1591-4","article-title":"The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K\/AKT signaling","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0155","first-page":"346","article-title":"Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation","volume":"7","author":"Ahmed","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","article-title":"Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality","volume":"22","author":"Xu","year":"2014","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bcp.13780","article-title":"The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth","volume":"85","author":"Amin","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1165\/rcmb.2012-0244OC","article-title":"Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription\u20133 activity independently of the liver kinase B1\u2013AMP-Activated protein kinase pathway","volume":"49","author":"Lin","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0175","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1164\/rccm.201407-1395OC","article-title":"Survival of patients with stage IV lung cancer with diabetes treated with metformin","volume":"191","author":"Lin","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cllc.2011.10.002","article-title":"Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan","volume":"13","author":"Lai","year":"2012","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2015.08.024","article-title":"Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes","volume":"369","author":"Chen","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0190","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3332\/ecancer.2017.781","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014chloroquine and hydroxychloroquine as anti-cancer agents","volume":"11","author":"Verbaanderd","year":"2017","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2015.99","article-title":"Emerging strategies to effectively target autophagy in cancer","volume":"35","author":"Rebecca","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13046-018-0938-5","article-title":"Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages","volume":"37","author":"Li","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/bjc.1993.189","article-title":"Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study","volume":"67","author":"Millward","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0210","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3332\/ecancer.2015.513","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014clarithromycin as an anti-cancer agent","volume":"9","author":"Van Nuffel","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0215","doi-asserted-by":"crossref","first-page":"87271","DOI":"10.18632\/oncotarget.13536","article-title":"Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-\u03baB\/GLUT1 axis","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-016-2162-z","article-title":"The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts","volume":"16","author":"Mediavilla-Varela","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0225","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.bbrc.2014.03.047","article-title":"Inhibitory effect of Disulfiram\/copper complex on non-small cell lung cancer cells","volume":"446","author":"Duan","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fonc.2016.00142","article-title":"Rationally repurposing ruxolitinib (Jakafi\u00ae) as a solid tumor therapeutic","volume":"6","author":"Tavallai","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0235","first-page":"3339","article-title":"Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis","volume":"5","author":"Wang","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0240","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JTO.0b013e3182435aa6","article-title":"A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA\/IIIB non-small cell lung cancer: a report of toxicities and clinical response","volume":"7","author":"Rengan","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2019.10.019_bib0245","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju250","article-title":"Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing","volume":"106","author":"Haura","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.semcancer.2019.10.019_bib0250","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju204","article-title":"Selective antitumor activity of ibrutinib in EGFR-mutant non\u2013small cell lung cancer cells","volume":"106","author":"Gao","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0255","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/fcp.12199","article-title":"Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function","volume":"30","author":"Jia","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0260","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.18632\/oncotarget.3174","article-title":"Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0265","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.drudis.2012.07.017","article-title":"Applications of Connectivity Map in drug discovery and development","volume":"17","author":"Qu","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0270","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2105-9-258","article-title":"A simple and robust method for connecting small-molecule drugs using gene-expression signatures","volume":"9","author":"Zhang","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0275","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004068","article-title":"Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data","volume":"11","author":"Fortney","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0285","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","article-title":"Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer","volume":"186","author":"Yeh","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0290","doi-asserted-by":"crossref","first-page":"17989","DOI":"10.1073\/pnas.1421410111","article-title":"Bisphosphonates inactivate human EGFRs to exert antitumor actions","volume":"111","author":"Yuen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0295","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JTO.0b013e31820c9e3c","article-title":"The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin","volume":"6","author":"Srirangam","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0300","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0305","first-page":"3560","article-title":"Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo","volume":"5","author":"Chen","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0310","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10637-010-9450-2","article-title":"Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin","volume":"29","author":"Hwang","year":"2011","journal-title":"Invest New Drug"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0315","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1634\/theoncologist.2015-0064","article-title":"Therapeutic effects of repurposed therapies in non-small cell lung cancer: what is old is new again","volume":"20","author":"Saxena","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0320","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10637-009-9319-4","article-title":"Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations","volume":"28","author":"Park","year":"2010","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0325","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1049\/iet-syb.2013.0035","article-title":"In silico identification of potential targets and drugs for non-small cell lung cancer","volume":"8","author":"Huang","year":"2014","journal-title":"IET Syst. Biol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0330","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00003495-198427050-00002","article-title":"Auranofin","volume":"27","author":"Chaffman","year":"1984","journal-title":"Drugs"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0335","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.18632\/oncotarget.6516","article-title":"Auranofin-mediated inhibition of PI3K\/AKT\/mTOR axis and anticancer activity in non-small cell lung cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0345","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3332\/ecancer.2015.568","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014nitroglycerin as an anti-cancer agent","volume":"9","author":"Sukhatme","year":"2015","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0350","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1038\/onc.2017.153","article-title":"A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer","volume":"36","author":"Choi","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0355","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0360","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/JTO.0000000000000173","article-title":"LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT","volume":"9","author":"Kaufman","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0365","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12935-014-0151-3","article-title":"Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines","volume":"15","author":"Lam","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.semcancer.2019.10.019_bib0370","doi-asserted-by":"crossref","DOI":"10.1142\/S0219633619500147","article-title":"Discovery of novel anaplastic lymphoma kinase inhibitors: structure and energy based pharmacophore strategy","volume":"18","author":"James","year":"2019","journal-title":"J. Theor. Comput. Chem."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0375","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1078-0432.CCR-15-1601","article-title":"Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer","volume":"23","author":"Chong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0380","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12859-016-0941-9","article-title":"Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology","volume":"17","author":"Zhao","year":"2016","journal-title":"BMC Bioinformatics"},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.10.019_bib0385","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0390","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0395","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0400","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein-ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0405","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10822-007-9114-2","article-title":"Surflex-Dock 2.1: robust performance from ligand energetic modelling, ring flexibility and knowledge-based search","volume":"21","author":"Jain","year":"2007","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003302","article-title":"A comprehensive survey of small-molecule binding pockets in proteins","volume":"9","author":"Gao","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0415","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/ci060003g","article-title":"Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogeonics databases","volume":"46","author":"Nidhi","year":"2006","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/c160017a018","article-title":"The generation of a unique machine description for chemical Structures-A technique developed at chemical abstracts service","volume":"5","author":"Morgan","year":"1965","journal-title":"J. Chem. Doc."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0425","series-title":"Cheminformatics in Drug Discovery; Oprea, T. I., Ed.","first-page":"223","article-title":"WOMBAT: world of molecular bioactivity","author":"Olah","year":"2004"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0430","doi-asserted-by":"crossref","unstructured":"Cao DS, Liang DZ, Deng Z, Hu QN, He M, Xu QS, et al. Genome-scale screening of drug-target associations relevant to Ki using a chemogenomics approach PLoS One; 8:e57680.","DOI":"10.1371\/journal.pone.0057680"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0435","doi-asserted-by":"crossref","first-page":"D198","DOI":"10.1093\/nar\/gkl999","article-title":"BindingDB: a web-accesible database of experimentally determine protein-ligand binding affinities","volume":"35","author":"Liu","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0440","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1021\/acs.jcim.5b00330","article-title":"Target-based drug repositioning using large-scale chemical-protein interactome data","volume":"55","author":"Sawada","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0445","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/acs.molpharmaceut.6b00248","article-title":"Deep learning applications of drugs and drug repurposing using transcriptomic data","volume":"13","author":"Aliper","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0450","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btz418","article-title":"deepDR: a network-based deep learning approach to in silico drug repositioning","author":"Zeng","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0455","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mrfmmm.2017.08.003","article-title":"Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer","volume":"806","author":"Anoosha","year":"2017","journal-title":"Mutat. Res."},{"issue":"13","key":"10.1016\/j.semcancer.2019.10.019_bib0460","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2174\/1568026619666190618142432","article-title":"Forging new scaffolds from old: combining scaffold hopping and hierarchical virtual screening for identifying novel Bcl-2 inhibitors","volume":"19","author":"Kanakaveti","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"6","key":"10.1016\/j.semcancer.2019.10.019_bib0465","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/1568026619666190304143354","article-title":"Influence of amino acid mutations and small molecules on targeted inhibition of proteins involved in Cancer","volume":"19","author":"Kanakaveti","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"11","key":"10.1016\/j.semcancer.2019.10.019_bib0470","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98921","article-title":"Repurposing sertraline sensitizes non\u2013small cell lung cancer cells to erlotinib by inducing autophagy","volume":"3","author":"Jiang","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0475","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1093\/bioinformatics\/btu323","article-title":"Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy","volume":"30","author":"Kim","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0480","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7150\/jca.12191","article-title":"Expression profiling identifies bezafibrate as potential therapeutic drug for lung adenocarcinoma","volume":"6","author":"Liu","year":"2015","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0485","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/s12859-015-0845-0","article-title":"Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory","volume":"17","author":"Huang","year":"2016","journal-title":"In BMC bioinformatics BioMed Central"},{"key":"10.1016\/j.semcancer.2019.10.019_bib0490","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent advances in drug repositioning for the discovery of new anticancer drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0495","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/0008-5472.CAN-11-0691","article-title":"Itraconazole inhibits angiogenesis and tumor growth in non\u2013small cell lung cancer","volume":"71","author":"Aftab","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0500","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.114.218644","article-title":"The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer","volume":"352","author":"Wang","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0505","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1210\/jc.2011-2671","article-title":"Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing","volume":"97","author":"Zhang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0510","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-07-0334","article-title":"Incorporating bortezomib into the treatment of lung cancer","volume":"13","author":"Davies","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0515","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1152\/ajpcell.00225.2012","article-title":"Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis","volume":"304","author":"Chanvorachote","year":"2012","journal-title":"Am. J. Physiol., Cell Physiol."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0520","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2016.02.120","article-title":"Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-\u03b2-catenin axis","volume":"472","author":"Li","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2019.10.019_bib0525","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.08.009","article-title":"Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells","volume":"144","author":"Kim","year":"2017","journal-title":"Biochem. Pharmacol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19301488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19301488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:49:31Z","timestamp":1760917771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X19301488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":105,"alternative-id":["S1044579X19301488"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.019","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}